Sigma 1 receptor activation improves retinal structure and function in the Rho
(+)-pentazocine
Photoreceptor cells
Retinal degeneration
Rhodopsin P23H
Visual acuity
Journal
Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
12
12
2022
revised:
17
03
2023
accepted:
27
03
2023
pmc-release:
01
05
2024
medline:
28
4
2023
pubmed:
2
4
2023
entrez:
1
4
2023
Statut:
ppublish
Résumé
Retinitis pigmentosa (RP) is a group of devastating inherited retinal diseases that leads to visual impairment and oftentimes complete blindness. Currently no cure exists for RP thus research into prolonging vision is imperative. Sigma 1 receptor (Sig1R) is a promising small molecule target that has neuroprotective benefits in retinas of rapidly-degenerating mouse models. It is not clear whether Sig1R activation can provide similar neuroprotective benefits in more slowly-progressing RP models. Here, we examined Sig1R-mediated effects in the slowly-progressing Rho
Identifiants
pubmed: 37003581
pii: S0014-4835(23)00083-0
doi: 10.1016/j.exer.2023.109462
pmc: PMC10155485
mid: NIHMS1891414
pii:
doi:
Substances chimiques
Rhodopsin
9009-81-8
rho GTP-Binding Proteins
EC 3.6.5.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109462Subventions
Organisme : NEI NIH HHS
ID : P30 EY031631
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY012830
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY028103
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Références
Vision (Basel). 2016 May 09;1(1):
pubmed: 31740628
Invest Ophthalmol Vis Sci. 2011 Dec 28;52(13):9728-36
pubmed: 22110080
Mol Neurodegener. 2017 Sep 19;12(1):68
pubmed: 28927431
J Neurosci Res. 2022 Apr;100(4):1063-1083
pubmed: 35165923
Invest Ophthalmol Vis Sci. 2020 Nov 2;61(13):3
pubmed: 33137196
J Biol Chem. 2011 Mar 25;286(12):10551-67
pubmed: 21224384
Exp Eye Res. 2015 Mar;132:64-72
pubmed: 25616094
Brain Res. 1996 Sep 16;733(2):219-30
pubmed: 8891305
Stem Cell Res Ther. 2019 Feb 26;10(1):68
pubmed: 30808416
Br J Pharmacol. 2003 Mar;138(5):941-9
pubmed: 12642396
Prog Retin Eye Res. 2018 Mar;63:107-131
pubmed: 29097191
Surv Ophthalmol. 1999 Jan-Feb;43(4):321-34
pubmed: 10025514
Vision Res. 2007 Mar;47(5):624-33
pubmed: 17267005
J Pharmacol Sci. 2015 Jan;127(1):17-29
pubmed: 25704014
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4545-4558
pubmed: 28877319
Neuroscience. 1998 Mar;83(2):413-28
pubmed: 9460750
Cell Death Dis. 2019 Jul 18;10(8):547
pubmed: 31320609
J Comp Neurol. 2007 Jan 10;500(2):222-38
pubmed: 17111372
J Biol Chem. 2014 Mar 28;289(13):9288-303
pubmed: 24515108
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4611-6
pubmed: 15557474
Sci Rep. 2021 Aug 11;11(1):16356
pubmed: 34381136
Vision Res. 2002 Feb;42(4):517-25
pubmed: 11853768
Mol Ther Nucleic Acids. 2016 Nov 22;5(11):e389
pubmed: 27874856
J Pharmacol Exp Ther. 1982 Nov;223(2):284-90
pubmed: 6290634
Prog Retin Eye Res. 2018 Nov;67:130-149
pubmed: 30075336
Exp Eye Res. 2002 Dec;75(6):723-30
pubmed: 12470974
Neuron. 1992 Nov;9(5):815-30
pubmed: 1418997
Orphanet J Rare Dis. 2006 Oct 11;1:40
pubmed: 17032466
Trends Neurosci. 2013 Jul;36(7):385-95
pubmed: 23601133
Free Radic Biol Med. 2019 Apr;134:604-616
pubmed: 30743048
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):5
pubmed: 32150247
Redox Biol. 2019 Jun;24:101199
pubmed: 31026769
Trends Pharmacol Sci. 2016 Apr;37(4):262-278
pubmed: 26869505
Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):86-95
pubmed: 11687279
Nat Commun. 2017 Mar 14;8:14716
pubmed: 28291770
J Clin Invest. 2020 Apr 1;130(4):2054-2068
pubmed: 32175920
Sci Rep. 2021 Nov 9;11(1):21975
pubmed: 34753986
Trends Mol Med. 2005 Apr;11(4):177-85
pubmed: 15823756
Brain. 2014 Jul;137(Pt 7):1998-2014
pubmed: 24755275
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):E3764-72
pubmed: 27298364
Sci Transl Med. 2011 Jun 22;3(88):88ra54
pubmed: 21697530